Karen L. Smith sold $44k of AUPH
director at Aurinia Pharmaceuticals Inc.. 5,241 shares at an average of $8.43, traded Nov 11, 2024, filed Nov 12, 2024.
Score components
- +15RoleDirector
- +6Trade size$44k at market
- +10Share of holdings soldSold 29% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.6%, 3m -9.2%, 6m -6.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001600620-24-000114, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | MOption exercise Common Stock | +17,913 | - | - | 17,913 | Nov 12, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock | -5,241 | $8.43 | $44k | 12,672 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Restricted Stock Unitsderivative | -17,913 | $0.00 | $0 | 0 | Nov 12, 2024 |
Related signals
Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $190k 11,939 shares | -2% | |
| 30Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $356k 20,975 shares | -3% | |
| 53Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $12M 814,606 shares | +7% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $13M 900,000 shares | +8% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $14M 1,300,000 shares | +13% | |
| 32Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $210k 20,000 shares | -13% | |
| 38Weak | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $68k 8,305 shares | -5% | |
| 48Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $13M 1,600,000 shares | +19% | |
| 65Notable | Aurinia Pharmaceuticals Inc. | Matthew Maxwell Donley Chief Operating Officer | $994k 124,893 shares | -16% | |
| 60Notable | Aurinia Pharmaceuticals Inc. | Stephen P. Robertson EVP, General Counsel | $975k 122,479 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.